Definition

A humanized immunoglobulin G1 kappa (IgG1k) monoclonal antibody directed against leukocyte-associated immunoglobulin-like receptor 1 (LAIR1; LAIR-1; CD305), with potential antineoplastic activity. Upon administration, anti-LAIR1 monoclonal antibody NC525 targets, binds to and inhibits LAIR1-mediated downstream survival signaling. In addition, NC525 induces Fc-mediated antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). This inhibits survival of LAIR1-expressing acute myeloid leukemia (AML) leukemic stem cells (LSCs) and blast cells, and decreases tumor cell proliferation. LAIR1, an immune inhibitory checkpoint receptor, is overexpressed in AML LSCs and blast cells while having a minimal expression on normal, healthy hematopoietic stem cells (HSCs.). LAIR1 plays a key role in mediating survival signaling in these tumor cells.